Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07148089 · ClinicalTrials.gov registry record · Phase 1
A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)
A Phase 1 study of Catecholaminergic Polymorphic Ventricular Tachycardia, sponsored by Solid Biosciences.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 5
- Study locations
NCT07148089 is a Phase 1 study of Catecholaminergic Polymorphic Ventricular Tachycardia that is actively recruiting participants, run by Solid Biosciences. The registered enrollment target is 18 participants. The trial reports 5 study locations across 5 states.
The verdict
NCT07148089, a Phase 1 study of Catecholaminergic Polymorphic Ventricular Tachycardia, is actively recruiting participants, sponsored by Solid Biosciences.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety data in adult participants. Cohort 1 and Cohort 2 (optional for dose exploration) will include participants ≥ 18 years of age. Cohort 3 will include participants ≥ 7 to \< 18 years of age and will be initiated following data and safety monitoring board (DSMB) recommendations. Participants will be monitored for 5 years post-administration of SGT-501 including the active treatment period (1 year) and long-term follow-up (LTFU) (4 years) period.
Conditions Studied
Interventions
- DRUG SGT-501
Study Locations (5)
Massachusetts
- Boston Children's Hospital - Boston
Minnesota
- Mayo Clinic - Rochester
Ohio
- Cleveland Clinic - Cleveland
Pennsylvania
- University of Pennsylvania - Philadelphia
British Columbia
- St. Paul's Hospital - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2026-02-23 |
| Est. Completion | 2031-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07148089
The ClinicalTrials.gov registry entry for NCT07148089 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Solid Biosciences, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Catecholaminergic Polymorphic Ventricular Tachycardia appearing as the primary indexed condition, and to 1 intervention - of which SGT-501 is the first listed.
NCT07148089 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Massachusetts, Minnesota, Ohio.
Frequently Asked Questions
What is clinical trial NCT07148089 about?
NCT07148089 is a clinical study titled "A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)". This is a Phase 1b, Multicenter, Open-Label, Dose Finding Study to Investigate the Safety and Tolerability of a Single Intravenous Dose of SGT-501 in participants with catecholaminergic polymorphic ventricular tachycardia (CPVT). The first-in-human (FIH) safety study will focus on obtaining safety d...
What is the current status of trial NCT07148089?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2026-02-23. Estimated completion is 2031-05.
What conditions does trial NCT07148089 study?
This clinical trial studies the following conditions: Catecholaminergic Polymorphic Ventricular Tachycardia.
What interventions are being tested in trial NCT07148089?
The interventions under investigation include: SGT-501 (DRUG).
Who is sponsoring clinical trial NCT07148089?
This trial is sponsored by Solid Biosciences, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07148089 being conducted?
This trial has 5 study locations across Massachusetts, Minnesota, Ohio, Pennsylvania, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Catecholaminergic Polymorphic Ventricular Tachycardia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.